{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:08:06Z","timestamp":1763510886782,"version":"3.45.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Zhuang Autonomous Region Health Commission scientific research project","award":["No. Z20210478\uff0cZ20210002\uff0cZ20200986"],"award-info":[{"award-number":["No. Z20210478\uff0cZ20210002\uff0cZ20200986"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23814-1","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:42:56Z","timestamp":1763134976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive analysis of ALYREF gene expression and its correlation with immunotherapy efficacy and circulating tumor cells in bladder cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Zhen","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengshu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangyun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baode","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"5","key":"23814_CR1","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70(5), 404\u2013423 (2020).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"23814_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75(1), 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"23814_CR3","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/MJT.0000000000000934","volume":"29","author":"VM Konala","year":"2022","unstructured":"Konala, V. M., Adapa, S. & Aronow, W. S. Immunotherapy in bladder cancer. Am. J. Ther. 29(3), e334\u2013e337 (2022).","journal-title":"Am. J. Ther."},{"issue":"1","key":"23814_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","volume":"197","author":"NM Donin","year":"2017","unstructured":"Donin, N. M. et al. Immunotherapy for the treatment of urothelial carcinoma. J. Urol. 197(1), 14\u201322 (2017).","journal-title":"J. Urol."},{"issue":"8","key":"23814_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41419-024-06959-1","volume":"15","author":"Y Jin","year":"2024","unstructured":"Jin, Y. et al. ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA. Cell Death Dis. 15(8), 578 (2024).","journal-title":"Cell Death Dis."},{"issue":"1","key":"23814_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41698-024-00737-0","volume":"8","author":"L Zhong","year":"2024","unstructured":"Zhong, L. et al. ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export. NPJ Precis. Oncol. 8(1), 243 (2024).","journal-title":"NPJ Precis. Oncol."},{"issue":"7","key":"23814_CR7","doi-asserted-by":"publisher","first-page":"e2401026","DOI":"10.1002\/smtd.202401026","volume":"9","author":"Z Zhou","year":"2025","unstructured":"Zhou, Z. et al. Circulating tumor cells culture: Methods, challenges, and clinical applications. Small Methods 9(7), e2401026 (2025).","journal-title":"Small Methods"},{"issue":"2","key":"23814_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2021.01.011","volume":"54","author":"RW Sayaman","year":"2021","unstructured":"Sayaman, R. W. et al. Germline genetic contribution to the immune landscape of cancer. Immunity 54(2), 367-386.e8 (2021).","journal-title":"Immunity"},{"issue":"D1","key":"23814_CR9","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan, H. et al. CancerSEA: A cancer single-cell state atlas. Nucleic Acids Res. 47(D1), D900\u2013D908 (2019).","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"23814_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48(4), 812\u2013830 (2018).","journal-title":"Immunity"},{"issue":"10031","key":"23814_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387(10031), 1909\u20131920 (2016).","journal-title":"Lancet"},{"doi-asserted-by":"publisher","unstructured":"Rose, T. L. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br. J. Cancer 125(9):1251\u20131260. https:\/\/doi.org\/10.1038\/s41416-021-01488-6 (2021). Epub 2021 Jul 22. Erratum in: Br. J. Cancer 126(8):1237 (2022).","key":"23814_CR12","DOI":"10.1038\/s41416-021-01488-6"},{"issue":"6","key":"23814_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser, D., Gruener, R. F. & Huang, R. S. oncoPredict: An R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 22(6), 260 (2021).","journal-title":"Brief Bioinform."},{"issue":"D1","key":"23814_CR14","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53(D1), D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"23814_CR15","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"1","key":"23814_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"15","key":"23814_CR17","doi-asserted-by":"publisher","first-page":"1482927","DOI":"10.3389\/fgene.2024.1482927","volume":"25","author":"Y Jing","year":"2024","unstructured":"Jing, Y. et al. Diagnostic value of 5 miRNAs combined detection for breast cancer. Front. Genet. 25(15), 1482927 (2024).","journal-title":"Front. Genet."},{"issue":"1","key":"23814_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12672-025-01990-w","volume":"16","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. Association of DBNDD1 with prognostic and immune biomarkers in invasive breast cancer. Discov. Oncol. 16(1), 218 (2025).","journal-title":"Discov. Oncol."},{"issue":"7","key":"23814_CR19","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.21037\/tcr-23-34","volume":"12","author":"Z Luo","year":"2023","unstructured":"Luo, Z. et al. Cytokine-induced apoptosis inhibitor 1: A comprehensive analysis of potential diagnostic, prognosis, and immune biomarkers in invasive breast cancer. Transl. Cancer Res. 12(7), 1765\u20131786 (2023).","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"23814_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12672-025-02032-1","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Visualization analysis of breast cancer-related ubiquitination modifications over the past two decades. Discov. Oncol. 16(1), 431 (2025).","journal-title":"Discov. Oncol."},{"issue":"13","key":"23814_CR21","doi-asserted-by":"publisher","first-page":"909324","DOI":"10.3389\/fimmu.2022.909324","volume":"11","author":"W Xu","year":"2022","unstructured":"Xu, W. et al. Immunogenomic characteristics of cell-death-associated genes with prognostic implications in bladder cancer. Front. Immunol. 11(13), 909324 (2022).","journal-title":"Front. Immunol."},{"issue":"12","key":"23814_CR22","doi-asserted-by":"publisher","first-page":"1025195","DOI":"10.3389\/fonc.2022.1025195","volume":"14","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Identification of adenylate cyclase 2 methylation in bladder cancer with implications for prognosis and immunosuppressive microenvironment. Front. Oncol. 14(12), 1025195 (2022).","journal-title":"Front. Oncol."},{"issue":"378","key":"23814_CR23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jconrel.2024.12.069","volume":"10","author":"S Du","year":"2025","unstructured":"Du, S. et al. PD-L1 peptides in cancer immunoimaging and immunotherapy. J. Control Release 10(378), 1061\u20131079 (2025).","journal-title":"J. Control Release"},{"issue":"1","key":"23814_CR24","first-page":"82","volume":"11","author":"Y Godiyal","year":"2024","unstructured":"Godiyal, Y. et al. Role of PD-1\/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy. Mil. Med. Res. 11(1), 82 (2024).","journal-title":"Mil. Med. Res."},{"issue":"283","key":"23814_CR25","doi-asserted-by":"publisher","first-page":"117141","DOI":"10.1016\/j.ejmech.2024.117141","volume":"5","author":"B Cheng","year":"2025","unstructured":"Cheng, B. et al. Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024). Eur. J. Med. Chem. 5(283), 117141 (2025).","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"23814_CR26","doi-asserted-by":"publisher","first-page":"107996","DOI":"10.1016\/j.jbc.2024.107996","volume":"300","author":"J Bhandari","year":"2024","unstructured":"Bhandari, J. et al. The molecular chaperone ALYREF promotes R-loop resolution and maintains genome stability. J. Biol. Chem. 300(12), 107996 (2024).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"23814_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-024-02055-2","volume":"23","author":"M Yu","year":"2024","unstructured":"Yu, M. et al. NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer. Mol. Cancer 23(1), 139 (2024).","journal-title":"Mol. Cancer"},{"key":"23814_CR28","doi-asserted-by":"publisher","first-page":"155392","DOI":"10.1016\/j.prp.2024.155392","volume":"260","author":"GM Seigel","year":"2024","unstructured":"Seigel, G. M. et al. ALYREF\/THOC4 expression and cell growth modulation in retinoblastoma. Pathol. Res. Pract. 260, 155392 (2024).","journal-title":"Pathol. Res. Pract."},{"issue":"24","key":"23814_CR29","doi-asserted-by":"publisher","first-page":"e2307639","DOI":"10.1002\/advs.202307639","volume":"11","author":"T Jin","year":"2024","unstructured":"Jin, T. et al. HnRNPA2B1 ISGylation regulates m6A-tagged mRNA selective export via ALYREF\/NXF1 complex to foster breast cancer development. Adv. Sci. 11(24), e2307639 (2024).","journal-title":"Adv. Sci."},{"issue":"1","key":"23814_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41420-024-01862-2","volume":"10","author":"Q Meng","year":"2024","unstructured":"Meng, Q. et al. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Cell Death Discov. 10(1), 97 (2024).","journal-title":"Cell Death Discov."},{"issue":"1","key":"23814_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13062-024-00477-y","volume":"19","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. NSUN2 relies on ALYREF to regulate Nrf2-mediated oxidative stress and alleviate Dox-induced liver injury. Biol. Direct 19(1), 32 (2024).","journal-title":"Biol. Direct"},{"issue":"1","key":"23814_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.7150\/ijbs.82316","volume":"20","author":"J Nulali","year":"2024","unstructured":"Nulali, J. et al. ALYREF-mediated RNA 5-methylcytosine modification promotes hepatocellular carcinoma progression via stabilizing EGFR mRNA and pSTAT3 activation. Int. J. Biol. Sci. 20(1), 331\u2013346 (2024).","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"23814_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40580-024-00466-x","volume":"11","author":"Y Yun","year":"2024","unstructured":"Yun, Y., Kim, S., Lee, S. N., Cho, H. Y. & Choi, J. W. Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy. Nano Converg. 11(1), 56 (2024).","journal-title":"Nano Converg."},{"issue":"1","key":"23814_CR34","doi-asserted-by":"publisher","first-page":"189236","DOI":"10.1016\/j.bbcan.2024.189236","volume":"1880","author":"D Janjua","year":"2025","unstructured":"Janjua, D., Chaudhary, A., Joshi, U., Tripathi, T. & Bharti, A. C. Circulating tumor cells in solid malignancies: From advanced isolation technologies to biological understanding and clinical relevance in early diagnosis and prognosis. Biochim. Biophys. Acta Rev. Cancer 1880(1), 189236 (2025).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23814-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23814-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23814-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:05:41Z","timestamp":1763510741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23814-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23814"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23814-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was acquired from all patients and the study was approved by the Ethics Committee of FAH-GMU (Institutional Review Board Approval Number: KY2021053) and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki and its latest amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"40032"}}